Despite recent advances in crystallography and the availability of G-protein-coupled receptor (GPCR) structures, little is known about the mechanism of their activation process, as only the b 2 adrenergic receptor (b 2 AR) and rhodopsin have been crystallized in fully active conformations. Here we report the structure of an agonist-bound, active state of the human M2 muscarinic acetylcholine receptor stabilized by a G-protein mimetic camelid antibody fragment isolated by conformational selection using yeast surface display. In addition to the expected changes in the intracellular surface, the structure reveals larger conformational changes in the extracellular region and orthosteric binding site than observed in the active states of the b 2 AR and rhodopsin. We also report the structure of the M2 receptor simultaneously bound to the orthosteric agonist iperoxo and the positive allosteric modulator LY2119620. This structure reveals that LY2119620 recognizes a largely pre-formed binding site in the extracellular vestibule of the iperoxo-bound receptor, inducing a slight contraction of this outer binding pocket. These structures offer important insights into the activation mechanism and allosteric modulation of muscarinic receptors.
Muscarinic acetylcholine receptors (M1-M5) are GPCRs that regulate the activity of a diverse array of central and peripheral functions in the human body, including the parasympathetic actions of acetylcholine 1 . The M2 muscarinic receptor subtype has a key role in modulating cardiac function and many important central processes, such as cognition and pain perception 1 . As it was among the first GPCRs to be purified 2 and cloned 3 , the M2 receptor has long served as a model system in GPCR biology and pharmacology. Muscarinic receptors have attracted particular interest owing to their ability to bind smallmolecule allosteric modulators 4 . Because allosteric sites are often less conserved than the orthosteric binding site, some ligands binding to allosteric sites show substantial subtype selectivity 5, 6 . Such agents hold promise for the development of drugs for the treatment of conditions such as diseases of the central nervous system and for metabolic disorders. Although crystal structures were recently obtained for inactive states of the M2 and M3 muscarinic receptors 7, 8 , there are no structures of a GPCR bound to a drug-like allosteric modulator.
The binding of an agonist to the extracellular side of a GPCR results in conformational changes that enable the receptor to activate heterotrimeric G proteins. Despite the importance of this process, only the b 2 AR and rhodopsin have been crystallized in fully active conformations [9] [10] [11] [12] [13] . Crystallization of active-state GPCRs has been challenging due to their inherent conformational flexibility and biochemical instability 14 . To understand the mechanistic details underlying GPCR activation and allosteric modulation better, we solved X-ray crystal structures of the M2 receptor bound to the high-affinity agonist iperoxo 15 alone and in combination with LY2119620, a positive allosteric modulator.
Conformational selection of nanobodies
Initial crystallization attempts with M2 receptor bound to agonists were unsuccessful, probably due to the flexibility of the intracellular receptor surface in the absence of a stabilizing protein. We thus sought to obtain a 'G-protein mimetic' nanobody for the M2 receptor, analogous to that used to facilitate crystallization of the b 2 AR in an active conformation 11 . Llamas were immunized with M2 receptor bound to the agonist iperoxo, and a post-immune single variable domain (V HH ) nanobody complementary DNA library was constructed and displayed on the surface of yeast ( Fig. 1a ).
An essential component for the selection of active-state stabilizing nanobodies was simultaneous staining of yeast with both agonist and inverse-agonist occupied M2 receptor populations, which were distinguishably labelled with separate fluorophores. This allowed the use of fluorescence-activated cell sorting (FACS) to select those clones binding only agonist-occupied receptor ( Fig. 1b ; see Methods). To ensure that the different fluorophore-conjugated receptors represent distinct receptor populations requires that at least one receptor population must be bound to an exceptionally high-affinity or irreversible ligand. We therefore developed a covalent muscarinic receptor agonist for use in selection experiments. This has precedent in an acetylcholine mustard 16 , which is thought to react with the binding-site residue Asp 103 3.32 (superscript numerals refer to the Ballesteros-Weinstein numbering system) to form a covalent adduct 17 . Accordingly, we synthesized an analogous 'iperoxo mustard', which we call FAUC123 (Supplementary Methods). We found that FAUC123 bound covalently and was able to induce activation of the M2 receptor (Extended Data Fig. 1 ), thereby allowing simultaneous staining of yeast with agonistand antagonist-bound M2 receptor labelled with distinct fluorophores for each population.
After nine rounds of conformational selection, almost all remaining yeast cell clones preferentially bound FAUC123-occupied receptor ( Fig. 1d ). Three clones in particular, Nb9-1, Nb9-8 and Nb9-20 ( Fig. 2a ; see Methods), showed strong, conformationally selective staining on yeast ( Fig. 2b ). All three nanobodies enhanced agonist affinity ( Fig. 2c ), indicating that they stabilize active states of the receptor. Nb9-8 was the most potent, with a half-maximum effective concentration (EC 50 ) of approximately 100 nM. At high concentrations, Nb9-8 enhanced the affinity of the M2 receptor for iperoxo to almost the same extent as that observed in the presence of the heterotrimeric G protein G i (Fig. 2d ).
M2 receptor was purified in the presence of 10 mM iperoxo, and we obtained crystals of iperoxo-bound M2 receptor in complex with Nb9-8 by lipidic mesophase crystallography. The structure was solved by microdiffraction at Advanced Photon Source beamline 23ID-D (Extended Data Table 1 ). Supplementing the optimized crystallization conditions with the positive allosteric modulator LY2119620 yielded crystals of M2 receptor simultaneously bound to both iperoxo and the modulator (see Methods). For all crystallization work, the agonist iperoxo was used rather than acetylcholine, as the latter is of lower affinity and is prone to hydrolysis.
Cytoplasmic changes on activation
A key feature of GPCR activation is an outward movement of the intracellular portion of transmembrane (TM) helices 5 and 6, creating a cavity large enough to accommodate the carboxy terminus of the G protein a-subunit 10, 13 . Although several GPCRs have been crystallized in complex with agonists, only the b 2 AR and rhodopsin show a fully active state with adequate space to allow G-protein binding (Extended Data Fig. 2 ). As anticipated on the basis of functional studies (Fig. 2) , Nb9-8 binds to the intracellular surface of the receptor (Fig. 3a ). There is a significant outward displacement at the intracellular side of TM6, together with a smaller outward movement of TM5 and a rearrangement of TM7 around the NPXXY motif ( Fig. 3b, d ).
Like the active states of rhodopsin and the b 2 AR, the active M2 receptor shows rearrangements of the highly conserved DRY motif at the intracellular side of TM3 and the NPXXY motif in TM7 ( Fig. 3c, d ).
In the active state of M2, Arg 121 3.50 of the DRY motif adopts an extended conformation virtually identical to that seen in metarhodopsin II and the b 2 AR-G s complex (Fig. 3c, e ), and Asp 120 3.49 is stabilized by a hydrogen bond with Asn 58 2.39 (Fig. 3c ). To assess the importance of Asn 58 2.39 for stabilization of the active conformation, we mutated it to alanine. The resulting mutant displayed normal ligand-binding properties, but impaired ability to activate G protein (Extended Data Fig. 3a and Extended Data Table 2 ). Hence, it is likely that Asn 58 2.39 either directly stabilizes the active conformation, or engages in direct interactions with G protein.
Similar to the DRY motif, the NPXXY region in TM7 shows significant rearrangements on activation ( Fig. 3d ). Most striking is a partial 'unwinding' of TM7 around Tyr 440 7.53 . This positions Tyr 440 7.53 of the NPXXY motif in close proximity to the highly conserved residue Tyr 206 5.58 (Fig. 3d ). Although these two residues are not close enough to interact directly, their proximity may allow formation of a watermediated hydrogen bond, as seen in the active-state structures of the b 2 AR 18 and rhodopsin 12 . Indeed, the position of these two tyrosine residues is highly similar in the active structures of rhodopsin, b 2 AR and the M2 receptor ( Fig. 3f ), indicating that this feature represents a hallmark of GPCR activation. In addition, a molecular dynamics study recently predicted that Tyr 206 5.58 and Tyr 440 7.53 interact in the active conformation of the M2 receptor 19 , although this model was in other ways dissimilar from the structures presented here.
To assess the importance of this interaction for M2 receptor activation, we mutated Tyr 206 5.58 to phenylalanine, eliminating its ability to interact with Tyr 440 7.53 via a bridging water molecule. The Y206F mutant receptor could no longer be activated by acetylcholine (Extended Data Fig. 3a ) and gave only a very weak functional response on treatment with iperoxo. In addition, agonist affinity was reduced by greater than tenfold (Extended Data M2 receptor were displayed on yeast as an amino-terminal fusion to Aga2, and subjected to magnetic selection to enrich clones that bind preferentially to agonist-occupied receptor. b, For selections, an aziridinium ion derivative of iperoxo called FAUC123 was synthesized, allowing covalent modification of the receptor. c, Yeast were stained simultaneously with agonist-occupied M2 receptor and antagonist-occupied receptor labelled with distinct fluorophores.
d, Yeast from each selection round (Rd1-9) were stained in this manner to assess selection progress, showing a clear enrichment first for non-selective binders (upper-right quadrants) followed by specific enrichment for agonistpreferring clones (lower-right quadrants). A single asterisk indicates a selection round using conformational selection. Two asterisks indicate a selection round using FACS.
Activation mechanism
Whereas activation of b 2 AR and rhodopsin is associated with modest conformational changes in the orthosteric ligand-binding site, marked structural changes are observed in the M2 receptor. The activated M2 receptor shows a small orthosteric binding site, which completely occludes the agonist iperoxo from solvent ( Fig. 4a, b) . Indeed, the muscarinic inverse agonist quinuclidinyl benzilate (QNB) is too large to be accommodated in this binding cavity, perhaps accounting for its ability to suppress basal activity of the M2 receptor. Within the active orthosteric binding pocket, the agonist iperoxo adopts a bent conformation ( Fig. 4c and Extended Data Fig. 4 ). Transmembrane helices 5, 6 and 7 move inward, towards the agonist, in the active M2 conformation. TM3, in contrast, undergoes a slight rotation about its axis, but has almost no inward motion towards the ligand. The largest differences between inactive and active states of the M2 receptor involve TM6, where an inward movement of 2 Å at the a-carbon of Asn 404 6.52 allows for formation of a hydrogen bond between its side chain and iperoxo.
Despite these activation-related structural changes, polar contacts between the agonist iperoxo and the receptor resemble those with QNB bound to the inactive M2 receptor. In particular, the conserved Asp 103 3.32 serves as a counter-ion to the ligand amine in both cases, and Asn 404 6.52 engages in hydrogen bonding with both ligands. The smaller size of iperoxo relative to QNB results in more limited hydrophobic contacts, however. This is particularly true along TM5, which engages the phenyl rings of QNB, but makes more limited hydrophobic contact with iperoxo in the active receptor conformation.
The hydrogen bond between Asn 404 6.52 and the iperoxo isoxazoline oxygen is analogous to the hydrogen bond between this residue and the QNB carbonyl in the inactive receptor state; however, the smaller size of iperoxo necessitates an inward motion of TM6 ( Fig. 4d, e ). To investigate the role of this hydrogen bond in receptor activation, we mutated Asn 404 6.52 to glutamine, which, due to the longer side chain, would allow TM6 to form a hydrogen bond with iperoxo in the inactive receptor. Consistent with a previous mutagenesis study 21 , the N404Q mutant receptor failed to bind detectable amounts of [ 3 H]-NMS, but retained the ability to bind [ 3 H]-QNB specifically, although with 163fold reduced affinity (Extended Data Table 2 ). Similarly, the binding affinities for acetylcholine and iperoxo were reduced, and although the N404Q mutant was able to activate G protein in response to both iperoxo and acetylcholine, the concentration-response curves were shifted to the right by about 100-fold (Extended Data Fig. 3a ), probably due to the reduced agonist-binding affinities. Nevertheless, it remains possible that a structural reorientation of Asn 404 6.52 also contributes to M2 receptor activation.
Like Asn 404 6.52 , Asp 103 3.32 has a central role in receptor binding to iperoxo, engaging the trimethyl ammonium ion. Cation-p interactions with Tyr 104 3.33 , Tyr 403 6.51 and Tyr 426 7.39 form an aromatic lid over the ligand amine ( Fig. 4f ). To assess the contribution of Asp 103 3.32 to receptor activation, we generated and analysed the D103E mutant M2 receptor, which abolished agonist-induced M2 receptor activation (Extended Data Fig. 3a ). The D103E mutant receptor bound [ 3 H]-NMS with wild-type-like affinity but showed greatly reduced affinities for acetylcholine (,120-fold) and iperoxo (,380-fold) (Extended Data Table 2 ), indicating that Asp 103 3.32 recognition of the ligand cation has a critical role in both agonist binding and receptor activation.
In the active state of the M2 receptor, the inward motion of the upper portion of TM6 allows Tyr 403 6.51 to form a hydrogen bond with Tyr 104 3.33 , which in turn forms a hydrogen bond to Tyr 426 7.39 ( Fig. 4f ), resulting in closure of the aforementioned tyrosine lid over the agonist. Hydrogen bonding of this lid seems to be an important feature of agonist binding and activation in muscarinic receptors: mutation of any of the three tyrosines to Phe leads to impaired agonist binding in the homologous M3 muscarinic receptor 22 , and mutation of Tyr 104 3.33 and Tyr 403 6.51 in the M2 receptor has a similar effect 23, 24 . It should be noted that the structure of active M2 receptor bound to other agonists, including acetylcholine, might show differences as compared to the iperoxo-bound structure presented here.
Allosteric modulation
Muscarinic receptors have long served as important model systems for understanding allosteric modulation of GPCR signalling 5,6,25 . The structures of the inactive M2 and M3 receptors confirmed that these Nb9-1: were selected for detailed characterization, each with entirely unique complementarity determining region (CDR) sequences. These three nanobodies were expressed on the surface of yeast, and characterized by flow cytometry staining with FAUC123-bound (that is, agonist bound) M2 receptor and tiotropium-bound (that is, antagonist occupied) receptor. b, Each of the three clones displayed a preference for agonist-occupied receptor to varying degrees. c, Purified nanobodies were tested in a concentration-response assay for their ability to suppress 
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receptors possess a large extracellular vestibule, which has been shown to bind to allosteric modulators 26, 27 . Situated directly above (that is, extracellular to) the orthosteric site, this cavity also shows a substantial contraction upon activation of the M2 receptor due to the rotation of TM6 (Fig. 4b ). The motion of TM6 thus provides a structural link among three regions of the receptor: the extracellular vestibule, the orthosteric binding pocket, and the intracellular surface. The structural coupling of these three regions probably accounts for the fact that allosteric modulators can affect the affinity and efficacy of orthosteric ligands and can also directly activate G proteins as allosteric agonists 28 . For a better understanding of how allosteric modulators act at GPCRs, we crystallized the iperoxo-occupied M2 receptor with LY2119620, a positive allosteric modulator ( Fig. 5a ). This agent has not been studied previously, so we characterized its affinity for the M2 receptor and its allosteric interaction with iperoxo (see Supplementary Methods). Radioligand binding assays revealed that LY2119620 has similar pharmacological properties to its congener, LY2033298 (ref. 29) (Extended Data Fig. 3b and Extended Data Table 3 ). It shows strong positive cooperativity with iperoxo, and mild negative cooperativity with the inverse agonist [ 3 H]-NMS. Whereas LY2119620 enhances the affinity of the M2 receptor for iperoxo, it does not significantly change the efficacy of this orthosteric agonist (Extended Data Table 3 ). We also observed that LY2119620 is capable of directly activating the M2 receptor, albeit with low potency and efficacy relative to iperoxo (Extended Data Table 3 ).
Crystals of the M2 receptor bound to LY2119620 grew under identical conditions to those without the modulator, and the structure revealed unambiguous electron density for LY2119620 in the extracellular vestibule (Extended Data Fig. 5 ). The modulator is positioned directly above the orthosteric agonist (Fig. 5b) , and it engages in extensive interactions with the extracellular vestibule. Specifically, the aromatic rings of the modulator are situated directly between Tyr 177 ECL2 (where ECL2 indicates extracellular loop 2) and Trp 422 7. 35 , forming a three-layered aromatic stack. Importantly, a previous mutagenesis study implicated Tyr 177 ECL2 as a likely contact for the LY2119620 congener, LY2033298, at the M2 muscarinic receptor 29 . Several polar interactions are also seen ( Fig. 5c ). In particular, Tyr 80 2.61 , Asn 410 6.58 and Asn 419 ECL3 form hydrogen bonds to the modulator, and Glu 172 ECL2 engages in a charge-charge interaction with the ligand piperidine. LY2119620 binds at a site directly superficial to the orthosteric site, separated only by the tyrosine lid, with Tyr 426 7.39 interacting with both ligands.
The structure of the M2-iperoxo-LY2119620 complex is largely the same as that of receptor and agonist without LY2119620, indicating that the allosteric binding site is largely pre-formed in the presence of agonist. The extracellular vestibule shows a slight additional contraction around the allosteric ligand (Extended Data Fig. 6 ). This subtle change stands in contrast to the substantial closure of the extracellular vestibule in the two active structures relative to the inactive conformation ( Fig. 5d ). A notable exception is Trp 422 7.35 , which adopts a vertical conformation in the presence of LY2119620 and a horizontal conformation with iperoxo alone (Extended Data Fig. 6b ). The vertical conformation of this residue in the M2-iperoxo-LY2119620 complex allows it to engage in an aromatic stacking interaction with the modulator, consistent with mutagenesis results implicating Trp 422 7.35 in the binding of other allosteric modulators 30 . The effect of mutagenesis of Trp 422 7.35 on LY2119620 affinity has not been tested, however. Closure of the LY2119620 binding site in the agonist-bound M2 receptor allows far more extensive interactions with the modulator than the inverse agonist-bound conformation (Fig. 5e ), probably accounting for the ability of the modulator to enhance agonist binding affinity by preferentially slowing agonist dissociation.
The closed, active conformation of the extracellular vestibule is largely the consequence of the inward motion of TM6, which directly contacts the allosteric modulator, the orthosteric agonist, and probably the G protein as well. Stabilization of the closed extracellular vestibule by LY2119620 and other allosteric modulators may directly stabilize the open, active conformation of the intracellular side of TM6, accounting for the phenomenon of allosteric agonism in addition to positive 
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cooperativity with orthosteric agonists. However, although the differences in TM6 between inactive and active structures can be described as a rigid-body motion, we cannot exclude the possibility that TM6 is flexible, allowing independent conformational changes in the G-protein binding site, the orthosteric site and the extracellular vestibule.
Conclusions
The structures presented here offer insights into the structural basis for muscarinic receptor activation and allosteric modulation by a drug-like molecule. In contrast to rhodopsin and the b 2 AR, extensive changes are seen in the orthosteric binding site and in the extracellular with changes highlighted as red arrows. d, A side view shows the inward motion of TM6, which is required for the formation of a hydrogen bond between Asn 404 6.52 and the agonist iperoxo. e, Activation thus involves a pivot of TM6, which moves inward in the orthosteric site and outward at the intracellular side. f, The closure of the binding pocket allows the formation of a hydrogen-bonded tyrosine lid, located superficial to the agonist. 
Inactive M2
Active M2 + LY2119620 
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vestibule upon M2 receptor activation. The structure of active M2 receptor bound to the allosteric modulator LY2119620 definitively establishes the extracellular vestibule as an allosteric binding site, and shows that the allosteric modulator induces few additional structural changes as compared to those seen with orthosteric agonist alone. The structures presented here offer only a single view of an active muscarinic receptor; more work will be required to identify additional active states that may exist. Nonetheless, the information presented here provides a structural framework for future studies of GPCR activation and allostery, and may facilitate the development of novel therapeutics.
METHODS SUMMARY
The human M2 muscarinic receptor was expressed in Sf9 insect cells and purified to homogeneity by nickel affinity chromatography, followed by Flag affinity and size exclusion chromatography. The nanobody Nb9-8 was identified by yeast surface display using a library derived from peripheral blood lymphocytes of a llama immunized with purified, iperoxo-occupied M2 receptor. Recombinant Nb9-8 was expressed in the periplasm of Escherichia coli strain BL21(DE3), and purified by nickel affinity chromatography followed by size exclusion chromatography. Crystallography was performed using lipidic mesophase methods, and data were collected by X-ray microdiffraction at Advanced Photon Source GM/CA beamlines 23ID-B and 23ID-D.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Determination of M2 activation via inositol phosphate assays. Agonistinduced activation of the human M2 muscarinic receptor was studied in inositol phosphate (IP) accumulation assays as described 31 . For M2 activation studies, COS-7 cells were transiently co-transfected with cDNAs encoding the human M2 receptor (Missouri S&T cDNA Resource Center) and the hybrid G protein Ga qi5 (Ga q protein with the last five amino acids at the C terminus replaced by the corresponding sequence of Ga i ; gift from The J. David Gladstone Institutes) 32 . Twenty-four hours after transfection, cells were transferred into 24-well plates at a density of 100,000 cells per well in a volume of 270 ml. After addition of 30 ml of myo-[ 3 H]inositol (specific activity 5 22.5 Ci mmol 21 , PerkinElmer), cells were incubated for 15 h. Then, medium was aspirated, the cells were washed with serumfree medium supplemented with 10 mM LiCl, and test compounds (diluted in serum-free medium supplemented with 10 mM LiCl) were added at 37 uC for 60 min. Cells were then lysed by adding 150 ml of ice-cold 0.1 M NaOH for 5 min. After neutralization with 50 ml of 0.2 M formic acid, the cell extract was diluted in buffer (5 mM sodium tetraborate, 0.5 mM Na-EDTA) and separated by anion-exchange chromatography using an AG1-X8 resin (Bio-Rad). After washing with water and elution buffer A (5 mM sodium tetraborate, 60 mM sodium formate) and again with water, total IP was eluted with 2.5 ml elution buffer B (1.0 M ammonium formate) and directly collected into scintillation counting vials. Radioactivity was measured by scintillation counting after adding 2.5 ml of Emulsifier-Safe (PerkinElmer). Data were analysed by normalizing disintergrations per minute (d.p.m.) values with 0% for the non-stimulated receptor and 100% for the full effect of the reference iperoxo. Concentration-response curves were fitted by nonlinear regression using the Graphpad Prism 5 software. Irreversible activation of the M2 receptor was tested at 1 nM FAUC123 in comparison to the reversible ligand iperoxo (1 nM). After incubation for 30 min, the antagonist atropine (1 mM) was added to one-half of the sample (buffer was added to the other half) and incubations were continued for an additional 90 min. Total IP accumulation was determined as described above. LY2119620 pharmacology. To characterize the allosteric interaction between LY2119620 and iperoxo, we performed radioligand binding and cellular functional assays at the wild-type human M2 muscarinic receptor stably expressed in a CHO FlpIn cell line. Increasing concentrations of LY2119620 caused a modest reduction in the specific binding of the orthosteric antagonist, [ 3 H]-NMS, indicating weak negative cooperativity, but robustly enhanced the potency of iperoxo to compete for [ 3 H]-NMS binding, indicating positive cooperativity with the agonist (Extended Data Fig. 3b ). Application of an allosteric ternary complex model 33, 34 to these data yielded the values shown in Extended Data Table 3 for ligand affinity and cooperativities with agonist and antagonist. We then investigated the functional effect of LY2119620 on M2 muscarinic receptor signalling via monitoring receptor-mediated [ 35 S]-GTPcS binding to activated G proteins, or phosphorylation of ERK1/2 (pERK/2). [ 35 S]-GTPcS binding was chosen as a proximal measure of receptor activation, whereas the pERK1/2 assay was chosen because it measures a downstream response that is also a point of convergence of multiple cellular pathways, some of them potentially G-protein independent. In both instances, LY2119620 caused receptor activation in its own right, indicating that the modulator can act as an allosteric agonist, while simultaneously enhancing the potency of iperoxo (Extended Data Fig. 3b ). Application of an operational model of allosterism 35 to these data yielded the parameter values shown in Extended Data Table 3 . Comparison of the binding and functional data indicated that there was no significant difference between any of the pK B estimates of the affinity of LY2119620 for the allosteric site on the free receptor between assays. There was also no significant difference between the cooperativity factors with iperoxo across the assays, indicating that the molecular mechanism of action of LY2119620 is consistent with positive modulation of agonist affinity only, with minimal additional effects on agonist efficacy. This is in contrast to the more complex behaviour previously noted with the congener, LY2033298, at the M2 receptor 29 . Full methods details are available in the Supplementary Methods. M2 muscarinic receptor expression and purification. The human M2 muscarinic receptor gene was modified to remove glycosylation sites, and to add an amino-terminal Flag epitope tag and a carboxy-terminal 83His tag. In addition, residues 233-374 of intracellular loop 3 were deleted. This region has previously been shown to be unstructured 36 and is not essential for G-protein coupling in the homologous M1 muscarinic receptor 37 . This construct was expressed in Sf9 insect cells using the BestBac baculovirus system (Expression Systems). Cells were infected at a density of 4 3 10 6 cells ml 21 and then incubated for two days at 27 uC. Receptor was extracted and purified in the manner described previously for the M3 muscarinic receptor 8 . Briefly, receptor was purified by Ni-NTA chromatography, Flag affinity chromatography and size exclusion chromatography. Llama immunization samples. M2 receptor was prepared as described above, and bound to iperoxo by including it at 10 mM starting at Flag wash steps and in all subsequent buffers. Receptor was reconstituted into phospholipid vesicles composed of DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids) and lipid A in a 10:1 (w:w) ratio, then aliquoted at 1 mg ml 21 receptor concentration and frozen in 100 ml aliquots before injection. Yeast display samples. M2 receptor was purified as described above with 1 mM atropine included in all buffers. Receptor was then labelled with a fivefold molar excess of biotin-NHS ester (Sigma-Aldrich) in buffer containing 25 mM HEPES pH 7.2. After a 30-min incubation at room temperature and a 30-min incubation on ice, unreacted label was quenched with 50 mM Tris pH 8. Directly labelled samples with fluorophore-NHS esters were prepared in a similar manner. Receptor was then desalted into buffer containing either 10 mM tiotropium, 10 mM iperoxo, or buffer containing no ligand. Receptor eluted in buffer containing no ligand was treated with 50 mM iperoxo mustard (FAUC123; see Supplementary Information for details) for 20 min at room temperature. Samples were then concentrated, aliquoted, and flash frozen with 20% (v/v) glycerol. Crystallization samples. M2 receptor for crystallization was prepared as described above. When bound to Flag resin, the sample was washed with a mix of dodecyl maltoside buffer (DDM) and buffer containing 0.2% lauryl maltose neopentyl glycol detergent (MNG; Anatrace). These buffers were mixed first in a 1:1 ratio (DDM:MNG buffer), then 1:4 and 1:10 ratios. At each step the 5 ml column was washed with 10 ml of buffer at a 1 ml min 21 flow rate, and all buffers contained 1 mM atropine. Finally, the column was washed with 10 ml MNG buffer, and then 10 ml of low detergent buffer with agonist (0.01% MNG, 0.001% cholesterol hemisuccinate, 20 mM HEPES pH 7.5, 100 mM NaCl, 10 mM iperoxo). The sample was eluted, mixed with a 1.5-fold stoichiometric excess of Nb9-8 and a second nanobody, NbB4. This nanobody binds to an epitope different from Nb9-8, but was not resolved in the crystal structure. After mixing, the sample was incubated 30 min on ice, then concentrated and purified by size exclusion in low detergent buffer. Eluted protein was concentrated to A 280 5 96, and frozen in liquid nitrogen in 7 ml aliquots. Llama immunization. One llama (Lama glama) was immunized for 6 weeks with 1 mg receptor in total. Peripheral blood lymphocytes were isolated from the immunized animal to extract total RNA. cDNA was prepared using 50 mg of total RNA and 2.5 mg of oligo-dN6primer. Nanobody open reading frames were amplified as described 38 . Post-immune M2 receptor llama nanobody library construction. Nanobody V HH fragments were amplified by PCR using the primers pYalNB80AMPF (59-C ATTTTCAATTAAGATGCAGTTACTTCGCTGTTTTTCAATATTTTCTGTT ATTGCTAGCGTTTTAGCAATGGCCCAGGTGCAGCTGCAGGAG-39) and pYalNB80AMPR (59-CCACCAGATCCACCACCACCCAAGTCTTCTTCGGA GATAAGCTTTTGTTCGGATCCTGAGGAGACGGTGACCTGGGTCCC-39). The PCR products were then co-transformed with linearized pYal into yeast strain EBY100 as for the Nb80 affinity-maturation library, yielding a library size of 0.6 3 10 8 transformants. Selection of M2 G i -mimetic nanobodies from post-immune M2 llama nanobody library. For the first round of selection, counter-selection was performed against the b 2 receptor to remove yeast clones that bind nonspecifically to membrane proteins or to secondary staining reagents. 1.0 3 10 9 of induced yeast were washed with PBEM buffer and then stained in 5 ml of PBEM buffer containing 1 mM biotinylated b 2 receptor liganded with carazolol for 1 h at 4 uC. Yeast were then stained with streptavidin-647 as a secondary reagent and magnetically labelled with anti-647 microbeads (Miltenyi) as described previously 18 . Positively labelled yeast were then removed by the use of an LD column (Miltenyi); the cleared flowthrough was then used for subsequent selection. Positive selection for clones recognizing the active state of the M2 receptor was performed by staining with 2 mM biotinylated M2 receptor bound to the agonist iperoxo in 5 ml PBEM buffer supplemented with 2 mM iperoxo for 1 h at 4 uC. Yeast were then washed, stained with streptavidin-647, and magnetically labelled with anti-647 microbeads, including 1 mM iperoxo in the PBEM buffer at all steps. Magnetic separation of M2 receptor-binding yeast clones was performed using an LS column (Miltenyi) following the manufacturer's instructions. Magnetically sorted yeast were re-suspended in SDCAA medium and cultured at 30 uC. Rounds 2-4 were selected in a similar manner, counter-selecting against 1 mM biotinylated b 2 receptor bound to carazolol and positively selecting using 1 mM biotinylated M2 receptor bound to iperoxo. For these rounds, the scale was reduced tenfold to 1 3 10 8 induced yeast and staining volumes of 0.5 ml.
Conformational selection was performed for rounds 5-9. For rounds 5-8, yeast were stained with 1 mM biotinylated M2 receptor pre-incubated with the highaffinity antagonist tiotropium for 1 h at 4 uC. Yeast were then fluorescently labelled with either streptavidin-647 or streptavidin-PE, and magnetically labelled with the corresponding anti-647 or anti-PE microbeads (Miltenyi). Depletion of inactivestate binders was carried out using an LS column. The cleared yeast were then positively selected by staining with 0.5 mM (rounds 5-7) or 0.1 mM (round 8) M2
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receptor pre-bound to iperoxo for 1 h at 4 uC. Yeast were then fluorescently labelled with either streptavidin-PE or streptavidin-647, using a fluorophore distinct from that used in the previous counter-selection step. Magnetic separation of agonist-occupied M2 receptor was performed using an LS column, as for steps 1-4. For round 9, two-colour FACS was performed. Induced yeast were simultaneously stained with 1 mM Alexa647-labelled M2 receptor reacted with iperoxo mustard and 1 mM Alexa488-labelled M2 receptor pre-bound with tiotropium for 1 h at 4 uC. Alexa647 positive/Alexa488 negative yeast were purified using a FACS Jazz cell (BD Biosciences) sorter. Post-sorted yeast were plated onto SDCAA-agar plates and the nanobody-encoding sequences of several colonies were sequenced. Full sequences of clones confirmed to enhance agonist affinity are: Nb9-1, QVQL QESGGGLVQAGGSLRLSCAASGHTFSSARMYWVRQAPGKEREFVAAISRSG FTYSADSVKGRFTISRDIANNTVYLQMNSLQPEDTAIYTCYAAYLDEFYNDY THYWGLGTQVTVSS; Nb9-8, QVQLQESGGGLVQAGDSLRLSCAASGFDFD NFDDYAIGWFRQAPGQEREGVSCIDPSDGSTIYADSAKGRFTISSDNAENTV YLQMNSLKPEDTAVYVCSAWTLFHSDEYWGQGTQVTVSS; Nb9-20, QVQL QESGGGLVQPEGSLTLACDTSGFTMNYYAIAWFRQAPEKEREGLATISSIDG RTYYADSVKGRFTISRDSAKNMVYLQMNNLRPEDTAVYYCSAGPDYSDYG DESEYWGQGTQVTVSS. Expression of MBP-nanobody fusions in E. coli. Nanobody sequences were subcloned into a modified pMalp2x vector (New England Biolabs) containing an N-terminal, 3C protease-cleavable maltose binding protein (MBP) tag and a C-terminal 83His tag. Plasmids were transformed into BL21(DE3) cells and protein expression induced in Terrific Broth by addition of IPTG to 1 mM at an OD 600 of 0.8. After 24 h of incubation at 22 uC, cells were collected and periplasmic protein was obtained by osmotic shock. MBP-nanobody fusions were purified by Ni-NTA chromatography and MBP was removed using 3C protease. Cleaved MBP was separated from the 83His tagged nanobodies by an additional Ni-NTA purification step. The 83His tag was subsequently removed using carboxypeptidase A. Expression and purification of G protein. Heterotrimeric G i was prepared by expression using a single baculovirus for the human Ga i1 subunit and a second, bicistronic virus for human Gb1 and Gc2 subunits. G protein was expressed in HighFive insect cells, and then purified as described previously for G s (ref. 10) . In brief, G protein was extracted with cholate, purified by Ni-NTA chromatography, detergent exchanged into dodecyl maltoside buffer, and then purified by ion exchange and dialysed before use. M2 receptor radioligand binding assays with G protein and nanobody. M2 receptor was expressed and purified as described above. Receptor was then reconstituted into HDL particles consisting of apolipoprotein A1 and a 3:2 (mol:mol) mixture of the lipids POPC:POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and 1-hexadecanoyl-2-(9Zoctadecenoyl)-sn-glycero-3-phospho-(19-rac-glycerol) respectively, Avanti Polar Lipids). Binding reactions contained 50 fmol functional receptor, 0.6 nM [ 3 H] N-methyl scopolamine (NMS), 100 mM NaCl, 20 mM HEPES pH 7.5, 0.1% BSA, and ligands and nanobodies as indicated. Concentration-dependent effects of nanobodies were measured in the presence of 10 nM iperoxo. All reactions were carried out in a 500 ml volume. For samples containing G protein, purified G i heterotrimer from insect cells was added to the reactions at a 1,000-fold dilution from a 200 mM stock, resulting in a large stoichiometric excess over receptor and diluting G protein below the detergent CMC to allow incorporation into HDL particles, essentially as described previously 39 . Reactions were mixed and then incubated for 2 h. Samples were then filtered on a 48-well harvester (Brandel) onto a filter which had been pre-treated with 0.1% polyethylenimine. All measurements were taken by liquid scintillation counting, and experiments were performed at least in triplicate. Site-directed mutagenesis. A mammalian expression plasmid coding for the human M2 muscarinic receptor (M2R-pcDNA3.11) was obtained from the Missouri S&T cDNA Resource Center. Mutant M2 receptors were generated by using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. The identity of all mutant M2 receptor constructs was confirmed by DNA sequencing. Transient expression of receptor constructs in COS-7 cells. Wild-type and mutant M2 receptors were transiently expressed in COS-7 cells grown in 100 mm dishes, as described previously 40 . For functional studies, the various receptor constructs (3 mg each) were co-expressed with a chimaeric G protein a-subunit (G qi5 ; 3 mg plasmid DNA) in which the last five amino acids of Ga q were replaced with the corresponding Ga i sequence 41 . Radioligand binding studies of mutant and wild-type M2 receptors. Acetylcholine bromide was purchased from Sigma. Iperoxo was a gift of Bristol Myers Squibb. [ 3 H]-NMS (85.5 Ci mmol 21 ) and 3-quinuclidinyl benzilate ([ 3 H]-QNB; 47.4 Ci mmol 21 ) were from PerkinElmer Life Sciences (Downers Grove). Radioligand binding studies were carried out with membranes prepared from transfected COS-7 cells as described 41 . Forty-eight hours after transfection, cells were collected and resuspended in 25 mM sodium phosphate buffer (pH 7.4) containing 5 mM MgCl 2 .
Membrane homogenates were prepared and re-suspended in the same buffer. [ 3 H]-NMS or [ 3 H]-QNB binding reactions were carried out in the presence of 9 mg of membrane protein for 3 h at room temperature (total volume of the incubation mixture: 0.5 ml). In saturation binding studies, six different concentrations of the radioligand were used ([ 3 H]-NMS, 0.3 nM to 10 nM; [ 3 H]-QNB, 0.05 nM to 20 nM). In competition binding assays, membrane homogenates were incubated with ten different concentrations of acetylcholine (13 nM to 1 mM) or iperoxo (0.13 nM to 10 mM) in the presence of a fixed concentration of radioligand (2 nM [ 3 H]-NMS for all receptors except N404Q; 15 nM [ 3 H]-QNB for N404Q and 0.5 nM [ 3 H]-QNB for wild-type M2 receptor). Nonspecific binding was determined in the presence of 10 mM atropine. Reactions were stopped by rapid filtration through GF/C filters. Data were analysed using Prism 4.0 software (GraphPad Software, Inc.). Calcium mobilization assay. COS-7 cells co-expressing wild-type or mutant M2 receptor and the hybrid G protein, G qi5 (ref. 41) , were incubated with increasing concentrations of agonists (acetylcholine, 5 nM to 50 mM; iperoxo, 50 pM to 0.5 mM), and increases in intracellular calcium levels were determined in 96-well plates using FLIPR technology (Molecular Devices), as described in detail previously 42, 43 . Agonist concentration-response curves were analysed using Prism 4.0 software. Crystallization. Purified M2 receptor was reconstituted into lipidic cubic phase by mixing with a 1.5-fold excess by mass of 10:1 (w:w) monoolein cholesterol lipid mix. Protein and lipid were loaded into glass syringes (Art Robbins Instruments), and then mixed 100 times by the coupled syringe method 44 . Samples of 30-100 nl in volume were spotted onto 96-well glass plates and overlaid en bloc with 600 nl precipitant solution for each well. Precipitant solution consisted of 10-20% PEG300, 100 mM HEPES pH 7.2-7.9, 1.2% 1,2,3-heptanetriol, and 20-80 mM EDTA pH 8.0. Identical conditions were used to crystallize LY2119620-receptor complexes, except that the overlay precipitant solution was supplemented with 500 mM LY2119620. Crystals grew in 24 h, and reached full size within 2 days. Crystals were then harvested in mesh grid loops (MiTeGen) with 10-50 crystals per loop and stored in liquid nitrogen before use. Data collection. Grids of crystals were rastered at Advanced Photon Source beamlines 23ID-B and 23ID-D. Initial rastering was performed with an 80 mm by 30 mm beam with fivefold attenuation and 1-s exposure, and regions with strong diffraction were sub-rastered with a 10 mm collimated beam with equivalent X-ray dose. Data collection was similarly performed with a 10 mm beam, but with no attenuation and exposures of typically 1-5 s. An oscillation width of 1-2 degrees was used in each case, and wedges of 5-10 degrees were compiled to create the final data sets. Data reduction and refinement. Diffraction data were processed in HKL2000 45 , and statistics are summarized in Extended Data Table 1 . The structure was solved using molecular replacement with the structure of the inactive M2 receptor (Protein Data Bank accession 3UON) and Nb80 (Protein Data Bank accession 3P0G) as search models in Phaser 46 . The resulting structure was iteratively refined in Phenix 47 
